These results offer a preclinical proof of concept to target the inflammation to inhibit cancer stem cells early for improving the treatment of pancreatic cancers, with immediate clinical implications for repositioning dual COX/5-LOX inhibitors in human trials for high risk patients. The gene discussed is ALOX5; the disease is pancreatic neoplasm.